Watch HOWL. Know when insiders buy.
One email the day a filing lands. Free.
HOWL
Werewolf Therapeutics, Inc.
0.96
+0.04 +4.79%
USD · close Sep 17
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $46.8MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$34.6MNET DEBT $10.1M52W 0.31 – 2.19SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | $7.2M | $3.7M | — | 0.08 | $6.6M | — | — | Jul 31 |
| Q1 2026 · Mar 31 | — | — | — | −$13.3M | −$13.5M | — | -0.28 | −$10.6M | — | — | Jul 31 |
| Q4 2025 · Dec 31derived | — | — | — | −$9.4M | −$8.4M | — | -0.17 | −$11M | $0 | −$11M | Mar 27 |
| Q3 2025 · Sep 30 | — | — | — | −$15.7M | −$16.4M | — | -0.36 | −$15.2M | $0 | −$15.2M | Nov 4 |
| Q2 2025 · Jun 30 | — | — | — | −$17.5M | −$18M | — | -0.40 | −$15.2M | $0 | −$15.2M | Jul 31 |
| Q1 2025 · Mar 31 | — | — | — | −$18M | −$18.1M | — | -0.40 | −$18.9M | $0 | −$18.9M | Jul 31 |
| Q4 2024 · Dec 31derived | — | — | — | −$20.3M | −$20.4M | — | -0.44 | −$14.3M | $123K | −$14.4M | Mar 27 |
| Q3 2024 · Sep 30 | — | — | — | −$17.1M | −$16.7M | — | -0.38 | −$12.5M | $3K | −$12.5M | Nov 4 |
| Q2 2024 · Jun 30 | — | — | — | −$19M | −$17.2M | — | -0.43 | −$14.2M | $17K | −$14.2M | Nov 4 |
| Q1 2024 · Mar 31 | — | — | — | −$17.2M | −$16.2M | — | -0.39 | −$15.3M | $111K | −$15.4M | Nov 4 |
| Q4 2023 · Dec 31derived | — | — | — | −$13M | −$12M | — | -0.33 | −$4.6M | $198K | −$4.8M | Mar 11 |
| Q3 2023 · Sep 30 | — | — | — | −$9.3M | −$8.3M | — | -0.23 | −$7.2M | $221K | −$7.4M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$60.7M | −$60.8M | — | -1.33 | −$60.3M | $0 | −$60.3M | — | — |
| FY2024 · to Dec 31 | — | — | −$73.6M | −$70.5M | — | -1.63 | −$56.2M | $254K | −$56.4M | — | — |
| FY2023 · to Dec 31 | — | — | −$40.5M | −$37.4M | — | -1.05 | −$32.6M | $769K | −$33.4M | — | — |
| FY2022 · to Dec 31 | — | — | −$56.1M | −$53.8M | — | -1.86 | −$40.6M | $3.6M | −$44.2M | — | — |
| FY2021 · to Dec 31 | — | — | −$50.1M | −$50M | — | -10.94 | −$42.9M | $498K | −$43.4M | — | — |
| FY2020 · to Dec 31 | — | — | −$22.4M | −$15M | — | -28.08 | −$18.6M | $560K | −$19.2M | — | — |
Every number comes from Werewolf Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.